Mustafa Khasraw

Follow

Generating author description...

All published works
Action Title Year Authors
+ CTNI-39. UPDATE ON GBM AGILE: A GLOBAL, PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA 2024 Andrew B. Lassman
Brian M. Alexander
Donald A. Berry
Nicholas Berry
Meredith Buxton
Howard Colman
Hui Gan
John de Groot
Macarena de la Fuente
Jan Drappatz
+ P27.11.A GLOBAL EXPANSION OF GBM AGILE: A PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA 2024 Michael Weller
Donald A. Berry
N Blondin
B Boulmay
Meredith Buxton
Olivier Chinot
Howard Colman
M de la Fuente
John de Groot
Jan Drappatz
+ CTNI-85. GBM AGILE PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GBM: RESULTS OF FIRST EXPERIMENTAL ARM, REGORAFENIB 2023 Patrick Y. Wen
Brian M. Alexander
Donald A. Berry
Meredith Buxton
Webster K. Cavenee
Howard Colman
John de Groot
Benjamin M. Ellingson
Gary Gordon
E M V Hyddmark
+ P11.29.B UPDATE ON GBM AGILE: A GLOBAL, PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA 2023 Michael Weller
Brian M. Alexander
Donald A. Berry
N Blondin
Meredith Buxton
Webster K. Cavenee
Howard Colman
John de Groot
M de la Fuente
François Ducray
+ Advances in Treatment of Isocitrate Dehydrogenase (IDH)-Wildtype Glioblastomas 2023 Hao‐Wen Sim
Selena Lorrey
Mustafa Khasraw
+ Abstract CT062: GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma 2023 Ingo K. Mellinghoff
Brian M. Alexander
Donald A. Berry
Nicholas Blondin
Meredith Buxton
Webster K. Cavenee
Howard Colman
John de Groot
Macarena I. de la Fuente
Benjamin M. Ellingson
+ PDF Chat CTNI-38. UPDATE ON GBM AGILE: A GLOBAL, PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA 2022 Meredith Buxton
Brian M. Alexander
Donald A. Berry
Webster K. Cavenee
Howard Colman
John de Groot
Benjamin M. Ellingson
Gary Gordon
Mustafa Khasraw
Andrew B. Lassman
+ PDF Chat P11.65.B GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple treatment regimens in newly diagnosed and recurrent glioblastoma 2022 Michael Weller
B. Ellingson
Barbara T. Alexander
Patrick Y. Wen
Erik P. Sulman
Howard Colman
Donald A. Berry
Kirk Tanner
Mustafa Khasraw
Maxine Lim
+ GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma. 2022 Timothy F. Cloughesy
Brian M. Alexander
Donald A. Berry
Howard Colman
John Frederick De Groot
Benjamin M. Ellingson
Gary Gordon
Mustafa Khasraw
Andrew B. Lassman
Eudocia Q. Lee
+ Leveraging external data in the design and analysis of clinical trials in neuro-oncology 2021 Rifaquat Rahman
Steffen Ventz
Jon McDunn
Bill Louv
Irmarie Reyes‐Rivera
Mei‐Yin C. Polley
Fahar Merchant
Lauren E. Abrey
Joshua E. Allen
Laura K. Aguilar
+ PDF Chat RTID-11. GBM AGILE: A GLOBAL, PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA 2020 Meredith Buxton
Brian M. Alexander
Donald A. Berry
Webster K. Cavenee
Howard Colman
John de Groot
Benjamin M. Ellingson
Gary Gordon
Mustafa Khasraw
Andrew B. Lassman
+ GBM AGILE: A global, phase II/III adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma. 2020 Meredith Buxton
Brian M. Alexander
Donald A. Berry
Webster K. Cavenee
Howard Colman
John Frederick De Groot
Benjamin M. Ellingson
Gary Gordon
Mustafa Khasraw
Andrew B. Lassman
Common Coauthors
Commonly Cited References
Action Title Year Authors # of times referenced
+ Design and Evaluation of an External Control Arm Using Prior Clinical Trials and Real-World Data 2019 Steffen Ventz
Albert Lai
Timothy F. Cloughesy
Patrick Y. Wen
Lorenzo Trippa
Brian M. Alexander
2
+ PDF Chat Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE 2017 Brian M. Alexander
Sujuan Ba
Mitchel S. Berger
Donald A. Berry
Webster K. Cavenee
Susan M. Chang
Timothy F. Cloughesy
Tao Jiang
Mustafa Khasraw
Wenbin Li
2
+ Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With Glioblastoma 2019 Brian M. Alexander
Lorenzo Trippa
Sarah Gaffey
Isabel Arrillaga‐Romany
Eudocia Q. Lee
Mikael L. Rinne
Manmeet S. Ahluwalia
Howard Colman
Geoffrey Fell
Evanthia Galanis
2
+ PDF Chat Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial 2017 Michael Weller
Nicholas Butowski
David Tran
Lawrence D. Recht
Michael Lim
Hal W. Hirte
Lynn S. Ashby
Laszlo Mechtler
Samuel Goldlust
FĂĄbio M. Iwamoto
2
+ PDF Chat The use of external control data for predictions and futility interim analyses in clinical trials 2021 Steffen Ventz
Leah A. Comment
Bill Louv
Rifaquat Rahman
Patrick Y. Wen
Brian M. Alexander
Lorenzo Trippa
2
+ A Weighting Analogue to Pair Matching in Propensity Score Analysis 2013 Liang Li
Tom Greene
1
+ The Use of Matched Sampling and Regression Adjustment to Remove Bias in Observational Studies 2006 Donald B. Rubin
1
+ PDF Chat A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study 2015 James M. Schuster
R. K. Lai
Lawrence D. Recht
David A. Reardon
Nina A. Paleologos
Morris D. Groves
Maciej M. Mrugała
Randy L. Jensen
Joachim M. Baehring
Andrew E. Sloan
1
+ On the definition of a confounder 2013 Tyler J. VanderWeele
Ilya Shpitser
1
+ PDF Chat Comparison of Error Rates in Single-Arm Versus Randomized Phase II Cancer Clinical Trials 2010 Hui Tang
Nathan R. Foster
Axel Grothey
Stephen M. Ansell
Richard M. Goldberg
Daniel J. Sargent
1
+ The Brave New World of clinical cancer research: Adaptive biomarker‐driven trials integrating clinical practice with clinical research 2015 Donald A. Berry
1
+ PDF Chat Use of historical control data for assessing treatment effects in clinical trials 2013 Kert Viele
Scott Berry
Beat Neuenschwander
Billy Amzal
Fang Chen
Nathan Enas
Brian P. Hobbs
Joseph G. Ibrahim
Nelson Kinnersley
Stacy Lindborg
1
+ PDF Chat Clinical Trial Designs for Predictive Biomarker Validation: Theoretical Considerations and Practical Challenges 2009 Sumithra J. Mandrekar
Daniel J. Sargent
1
+ Sample size re‐estimation: recent developments and practical considerations 2001 A. Lawrence Gould
1
+ PDF Chat An Introduction to Causal Inference 2010 Judea Pearl
1
+ PDF Chat The central role of the propensity score in observational studies for causal effects 1983 Paul R. Rosenbaum
Donald B. Rubin
1
+ Incorporating historical control data in planning phase II clinical trials 1990 Peter F. Thall
Richard Simon
1
+ Biomarker classifiers for identifying susceptible subpopulations for treatment decisions 2011 Wei‐Jiun Lin
James J. Chen
1
+ Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma 2013 Tracy T. Batchelor
Paul Mulholland
Bart Neyns
Burt Nabors
Mario Campone
Antje Wick
Warren Mason
Tom Mikkelsen
Surasak Phuphanich
Lynn S. Ashby
1
+ Assessment of futility in clinical trials 2006 Steven Snapinn
Mon‐Gy Chen
Qi Jiang
Tony Koutsoukos
1
+ PDF Chat Causal Inference for Statistics, Social, and Biomedical Sciences: An Introduction 2016 Carol Joyce Blumberg
1
+ PDF Chat An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825 2016 Haley Gittleman
D. Lim
Michael W. Kattan
Arnab Chakravarti
Mark R. Gilbert
Andrew B. Lassman
Simon S. Lo
Mitchell Machtay
Andrew E. Sloan
Erik P. Sulman
1
+ PDF Chat Harnessing the Power of Real‐World Evidence (RWE): A Checklist to Ensure Regulatory‐Grade Data Quality 2017 Rebecca A. Miksad
Amy P. Abernethy
1
+ PDF Chat Estimation of clinical trial success rates and related parameters 2017 Chi Heem Wong
Kien Wei Siah
Andrew W. Lo
1
+ Real-World Evidence and Real-World Data for Evaluating Drug Safety and Effectiveness 2018 Jacqueline Corrigan‐Curay
Leonard Sacks
Janet Woodcock
1
+ Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial 2018 Giuseppe Lombardi
Gian Luca De Salvo
Alba A. Brandes
Marica Eoli
Roberta RudĂ 
Marina Faedi
Ivan Lolli
Andrea Pace
Bruno Daniele
Francesco Pasqualetti
1
+ Evaluating the Use of Nonrandomized Real‐World Data Analyses for Regulatory Decision Making 2019 Jessica M. Franklin
Robert J. Glynn
David Martin
Sebastian Schneeweiß
1
+ PDF Chat To randomize, or not to randomize, that is the question: using data from prior clinical trials to guide future designs 2019 Alyssa M. Vanderbeek
Steffen Ventz
Rifaquat Rahman
Geoffrey Fell
Timothy F. Cloughesy
Patrick Y. Wen
Lorenzo Trippa
Brian M. Alexander
1
+ PDF Chat Sharing of clinical trial data and results reporting practices among large pharmaceutical companies: cross sectional descriptive study and pilot of a tool to improve company practices 2019 Jennifer Miller
Joseph S. Ross
Marc Wilenzick
Michelle M. Mello
1
+ PDF Chat Using Electronic Health Records to Derive Control Arms for Early Phase Single‐Arm Lung Cancer Trials: Proof‐of‐Concept in Randomized Controlled Trials 2019 Gillis Carrigan
Samuel Whipple
William B. Capra
Michael D. Taylor
Jeffrey S. Brown
Michael W. Lu
Brandon Arnieri
Ryan Copping
Kenneth J. Rothman
1
+ PDF Chat Examining the Use of Real‐World Evidence in the Regulatory Process 2019 Brett K. Beaulieu‐Jones
Samuel G. Finlayson
William Yuan
Russ B. Altman
Isaac S. Kohane
Vinay Prasad
Kun‐Hsing Yu
1
+ An efficient Bayesian platform trial design for borrowing adaptively from historical control data in lymphoma 2019 James Normington
Jiawen Zhu
Federico Mattiello
Somnath Sarkar
Brad Carlin
1
+ The Magic of Randomization versus the Myth of Real-World Evidence 2020 Rory Collins
Louise Bowman
Martin Landray
Richard Peto
1
+ PDF Chat A roadmap to using historical controls in clinical trials – by Drug Information Association Adaptive Design Scientific Working Group (DIA-ADSWG) 2020 Mercedeh Ghadessi
Rui Tang
Joey Tianyi Zhou
Rong Liu
Chenkun Wang
Kiichiro Toyoizumi
Chaoqun Mei
Lixia Zhang
C. Q. Deng
Robert A. Beckman
1
+ PDF Chat Real‐world evidence to support regulatory decision‐making for medicines: Considerations for external control arms 2020 Mehmet Burcu
Nancy A Dreyer
Jessica M. Franklin
Michael D. Blum
Cathy W. Critchlow
Eleanor M. Perfetto
Wei Zhou
1
+ PDF Chat <p>Synthetic and External Controls in Clinical Trials – A Primer for Researchers</p> 2020 Kristian Thorlund
Louis Dron
Jay Park
Edward J. Mills
1
+ GBM AGILE: A global, phase II/III adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma. 2020 Meredith Buxton
Brian M. Alexander
Donald A. Berry
Webster K. Cavenee
Howard Colman
John Frederick De Groot
Benjamin M. Ellingson
Gary Gordon
Mustafa Khasraw
Andrew B. Lassman
1
+ Externally Controlled Trials: Are We There Yet? 2020 Louis Larrouquère
Joris Giai
Jean‐Luc Cracowski
SĂŠbastien Bailly
Matthieu Roustit
1
+ Use of Real‐World Data to Emulate a Clinical Trial and Support Regulatory Decision Making: Assessing the Impact of Temporality, Comparator Choice, and Method of Adjustment 2020 Devin Abrahami
Richeek Pradhan
Hui Yin
Peter K. Honig
Elodie Baumfeld Andre
Laurent Azoulay
1
+ Informing single-arm clinical trials with external controls 2020 R Davi
Nirosha Mahendraratnam
Arnaub K. Chatterjee
C. Jill Dawson
Rachel E. Sherman
1
+ PDF Chat Use of Real-World Evidence to Support FDA Approval of Oncology Drugs 2020 Bruce A. Feinberg
Ajeet Gajra
Marjorie E. Zettler
Todd D. Phillips
Eli G. Phillips
Jonathan Kish
1
+ Single-arm Trials With External Comparators and Confounder Misclassification 2020 Michael Webster‐Clark
Michele JĂśnsson Funk
Til Stürmer‎
1
+ PDF Chat Methods for external control groups for single arm trials or <scp>long‐term</scp> uncontrolled extensions to randomized clinical trials 2020 John D. Seeger
Kourtney J. Davis
Michelle R. Iannacone
Wei Zhou
Nancy A Dreyer
Almut G. Winterstein
Nancy C. Santanello
Barry J. Gertz
Jesse A. Berlin
1
+ Randomized Controlled Trials Versus Real World Evidence: Neither Magic Nor Myth 2020 Hans‐Georg Eichler
Francesco Pignatti
Brigitte Schwarzer‐Daum
Ana Hidalgo‐Simon
Irmgard Eichler
Peter Arlett
A. J. B. Humphreys
Spiros Vamvakas
Nikolai C. Brun
Guido Rasi
1
+ Statistical adaptation to oncology drug development evolution 2020 Mingxiu Hu
Miao Yang
Yi Liu
1
+ PDF Chat Replication of Randomized, Controlled Trials Using Real-World Data: What Could Go Wrong? 2020 David Thompson
1
+ PDF Chat Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies 2020 Jessica M. Franklin
Elisabetta Patorno
Rishi Desai
Robert J. Glynn
David Martin
Kenneth Quinto
Ajinkya Pawar
Lily G. Bessette
Hemin Lee
Elizabeth M. Garry
1
+ PDF Chat Inefficiencies in phase II to phase III transition impeding successful drug development in glioblastoma 2020 Adithya Balasubramanian
Ashray Gunjur
Umbreen Hafeez
Siddharth Menon
Lawrence Cher
Sagun Parakh
Hui Gan
1
+ How to choose a time zero for patients in external control arms 2021 Daniel Backenroth
1
+ PDF Chat Evaluating eligibility criteria of oncology trials using real-world data and AI 2021 Ruishan Liu
Shemra Rizzo
Samuel Whipple
Navdeep Pal
Arturo LĂłpez Pineda
Michael W. Lu
Brandon Arnieri
Ying LĂź
William B. Capra
Ryan Copping
1